Pfiz­er dumps a fad­ing pipeline star, giv­ing up on its PC­SK9 drug bo­co­cizum­ab

Paul M. Rid­ker, MD, SPIRE clin­i­cal tri­als pro­gram

You can scratch any hopes you might have had that Pfiz­er could mount a come-from-be­hind win and seize the lead from Am­gen and Sanofi/Re­gen­eron in the race of PC­SK9 cho­les­terol drugs. The phar­ma gi­ant has de­cid­ed to drop its can­di­date, bo­co­cizum­ab, cit­ing wan­ing ef­fi­ca­cy re­sults, a poor mar­ket re­cep­tion for the pi­o­neers, signs of an im­mune re­sponse to the drug and side ef­fects that would have like­ly marred its de­but.

Pfiz­er will now slam the brakes on two late-stage stud­ies — Spire-1 and Spire-2 — de­signed to test their drug in 32,000 pa­tients, a mas­sive­ly ex­pen­sive en­deav­or that went look­ing for the kinds of out­comes da­ta that could win over pay­ers. And it’s tak­ing a $0.04 R&D charge on the move.

Pfiz­er’s shares dropped 2.2% on the de­ci­sion in pre-mar­ket trad­ing Tues­day.

The move marks the ter­mi­na­tion of one of the phar­ma gi­ant’s biggest late-stage clin­i­cal ef­forts, leav­ing it still in the hunt for new drugs that can whip up some en­thu­si­asm from an­a­lysts.

Am­gen and Sanofi/Re­gen­eron sparked big hopes for their fran­chise plays in this field, bat­tling each oth­er for first-mover po­si­tion and vow­ing to jump out in front in the strug­gle to seize a mar­ket worth bil­lions. So far, though, the com­pa­nies have been bru­tal­ly dis­ap­point­ed by the ane­mic ini­tial de­mand for these ther­a­pies, as pay­ers kick back on the cost. That soft launch com­bined with ev­i­dence that Pfiz­er’s drug may not have mea­sured up well, ev­i­dent­ly played a key role in the de­ci­sion to kill it af­ter spend­ing hun­dreds of mil­lions of dol­lars on de­vel­op­ment.

Bar­clays dis­cussed it with Pfiz­er ex­ecs, and came away with this con­clu­sion:

Of note, the de­ci­sion to dis­con­tin­ue bo­co­cizum­ab was not in­flu­enced by any on­go­ing out­comes da­ta or feed­back from the da­ta mon­i­tor­ing com­mit­tee; the tri­als are still blind­ed. In our view, the cul­prit was the pres­ence of an­ti-drug an­ti­bod­ies (ADAs). Of note, from the pub­lished phase 2 da­ta from bo­co­cizum­ab, the ADA rate was ~7%.  It seemed to us that the pres­ence of ADAs in some pa­tients on bo­co­cizum­ab be­came prob­lem­at­ic, with a mi­nor­i­ty of pa­tients hav­ing a ‘sub­stan­tial lev­el’ of ADAs and a larg­er num­ber hav­ing a high­er back­ground lev­el. In our view, this like­ly wouldn’t have af­fect­ed the over­all prob­a­bil­i­ty of suc­cess in the SPIRE-1 or SPIRE-2, but it would present chal­lenges com­mer­cial­ly, where Am­gen’s Repatha or Re­gen­eron’s Pralu­ent haven’t seen an ADA rate in that range. And it does ex­plain an at­ten­u­a­tion of LDL-C ef­fect with bo­co­cizum­ab.

Pfiz­er had al­ready read out da­ta from the first 4 of 6 stud­ies in the late-stage pro­gram, reg­u­lar­ly tout­ing its ef­fi­ca­cy and pro­mot­ing its mar­ket­ing hopes in the field. Now The Med­i­cines Com­pa­ny, part­nered with Al­ny­lam, will move up to the third spot in this race with a PC­SK9 drug that a may on­ly need twice-year­ly dos­ing.

Pfiz­er has one of the weak­est late-stage pipelines in Big Phar­ma, and this set­back was not­ed by sev­er­al an­a­lysts, in­clud­ing Leerink’s Sea­mus Fer­nan­dez, who said: “This re­moves an im­por­tant Ph3 pipeline prod­uct for PFE while elim­i­nat­ing a ma­jor pot’l com­peti­tor for AMGN (MP) and SNY/REGN.”

Aside from the new­ly ac­quired PARP ta­la­zoparib, the check­point in­hibitor avelum­ab part­nered with Mer­ck KGaA and the SGLT2 di­a­betes drug er­tugliflozin part­nered with Mer­ck, Pfiz­er doesn’t have much that’s new in late-stage stud­ies. Much of its Phase III ef­fort is now giv­en to biosim­i­lars.

Pfiz­er promised to hus­tle out the da­ta on its de­funct PC­SK9 drug for fur­ther dis­cus­sion.

“To hon­or the al­tru­ism of tri­al par­tic­i­pants, and to max­i­mize the clin­i­cal and sci­en­tif­ic knowl­edge de­rived from the halt­ed tri­als, Pfiz­er has com­mit­ted to en­sur­ing that the da­ta will be made avail­able to study lead­ers for in­de­pen­dent analy­sis and prompt pub­lic pre­sen­ta­tion. We be­lieve the avail­able da­ta will al­low us to test the core sci­en­tif­ic ques­tions posed by the over­all pro­gram which is in the best in­ter­est of pa­tients who vol­un­teered in these clin­i­cal tri­als, and for pa­tients world­wide who suf­fer from heart dis­ease,” stat­ed Paul M. Rid­ker, MD, Co-chair Ex­ec­u­tive Com­mit­tee, SPIRE clin­i­cal tri­als pro­gram and di­rec­tor for Car­dio­vas­cu­lar Dis­ease Pre­ven­tion, Brigham and Women’s Hos­pi­tal.

Paul Hudson, Sanofi CEO (Getty Images)

Sanofi CEO Paul Hud­son has $23B burn­ing a hole in his pock­et. And here are some hints on how he plans to spend that

Sanofi has reaped $11.1 billion after selling off a big chunk of its Regeneron stock at $515 a share. And now everyone on the M&A side of the business is focused on how CEO Paul Hudson plans to spend it.

After getting stung in France for some awkward politicking — suggesting the US was in the front of the line for Sanofi’s vaccines given American financial support for their work, versus little help from European powers — Hudson now has the much more popular task of managing a major cash cache to pull off something in the order of a big bolt-on. Or two.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca trum­pets the good da­ta they found for Tagris­so in an ad­ju­vant set­ting for NSCLC — but many of the ex­perts aren’t cheer­ing along

AstraZeneca is rolling out the big guns this evening to provide a salute to their ADAURA data on Tagrisso at ASCO.

Cancer R&D chief José Baselga calls the disease-free survival data for their drug in an adjuvant setting of early stage, epidermal growth factor receptor-mutated NSCLC patients following surgery “momentous.” Roy Herbst, the principal investigator out of Yale, calls it “transformative.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.

The Avance Clinical leadership team: CEO Yvonne Lungershausen, Sandrien Louwaars - Director Business Development Operations, Gabriel Kremmidiotis - Chief Scientific Officer, Ben Edwards - Chief Strategy Officer

How Aus­tralia De­liv­ers Rapid Start-up and 43.5% Re­bate for Ear­ly Phase On­col­o­gy Tri­als

About Avance Clinical

Avance Clinical is an Australian owned Contract Research Organisation that has been providing high-quality clinical research services to the local and international drug development industry for 20 years. They specialise in working with biotech companies to execute Phase 1 and Phase 2 clinical trials to deliver high-quality outcomes fit for global regulatory standards.

As oncology sponsors look internationally to speed-up trials after unprecedented COVID-19 suspensions and delays, Australia, which has led the world in minimizing the pandemic’s impact, stands out as an attractive destination for early phase trials. This in combination with the streamlined regulatory system and the financial benefits including a very favourable exchange rate and the R & D cash rebate makes Australia the perfect location for accelerating biotech clinical programs.

Pablo Legorreta, founder and CEO of Royalty Pharma AG, speaks at the annual Milken Institute Global Conference in Beverly Hills, California (Patrick T. Fallon/Bloomberg via Getty Images)

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

Pablo Legorreta is one of the most influential players in biopharma you likely never heard of.

Over the last 24 years, Legorreta’s Royalty Pharma group has become, by its own reckoning, the biggest buyer of drug royalties in the world. The CEO and founder has bought up a stake in a lengthy list of the world’s biggest drug franchises, spending $18 billion in the process — $2.2 billion last year alone. And he’s become one of the best-paid execs in the industry, reaping $28 million from the cash flow last year while reserving 20% of the cash flow, less expenses, for himself.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.

Dan O'Day, Gilead CEO (Andrew Harnik, AP Images)

UP­DAT­ED: Gilead leas­es part­ner rights to TIG­IT, PD-1 in a $2B deal with Ar­cus. Now comes the hard part

Gilead CEO Dan O’Day has brokered his way to a PD-1 and lined up a front row seat in the TIGIT arena, inking a deal worth close to $2 billion to align the big biotech closely with Terry Rosen’s Arcus. And $375 million of that comes upfront, with cash for the buy-in plus equity, along with $400 million for R&D and $1.22 billion in reserve to cover opt-in payments and milestones..

Hotly rumored for weeks, the 2 players have formalized a 10-year alliance that starts with rights to the PD-1, zimberelimab. O’Day also has first dibs on TIGIT and 2 other leading programs, agreeing to an opt-in fee ranging from $200 million to $275 million on each. There’s $500 million in potential TIGIT milestones on US regulatory events — likely capped by an approval — if Gilead partners on it and the stars align on the data. And there’s another $150 million opt-in payments for the rest of the Arcus pipeline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.

Roger Perlmutter, Merck R&D chief (YouTube)

UP­DAT­ED: Backed by BAR­DA, Mer­ck jumps in­to Covid-19: buy­ing out a vac­cine, part­ner­ing on an­oth­er and adding an­tivi­ral to the mix

Merck execs are making a triple play in a sudden leap into the R&D campaign against Covid-19. And they have more BARDA cash backing them up on the move.

Tuesday morning the pharma giant simultaneously announced plans to buy an Austrian biotech that has been working on a preclinical vaccine candidate, added a collaboration on another vaccine with the nonprofit IAVI and inked a deal with Ridgeback Biotherapeutics on an early-stage antiviral.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.

Bryan Roberts, Venrock

Ven­rock sur­vey shows grow­ing recog­ni­tion of coro­n­avirus toll, wan­ing con­fi­dence in ar­rival of vac­cines and treat­ments

When Venrock partner Bryan Roberts went to check the results from their annual survey of healthcare leaders, what he found was an imprint of the pandemic’s slow arrival in America.

The venture firm had sent their form out to hundreds of insurance and health tech executives, investors, officials and academics on February 24 and gave them two weeks to fill it out. No Americans had died at that point but the coronavirus had become enough of a global crisis that they included two questions about the virus, including “Total U.S. deaths in 2020 from the novel coronavirus will be:”.

David Hoey (Vaxxas)

In for the long vac­cine game, Mer­ck buys in­to patch de­liv­ery tech with pan­dem­ic po­ten­tial

When Merck dived into the R&D fray for a Covid-19 vaccine earlier this week, execs made it clear that they’re not necessarily looking to be first — with CEO Ken Frazier throwing cold water on the hotly-discussed 12- to 18-month timelines. But when it does emerge from behind, the pharma giant clearly expects to play a significant part.

Part of that will depend on next-generation delivery technology that reshapes the world’s imagination of a vaccine.

No­var­tis jumps in­to Covid-19 vac­cine hunt, as Big Phar­ma and big biotech com­mit to bil­lions of dos­es

After spending most of the pandemic on the sidelines, Novartis is offering its aid in the race to develop a Covid-19 vaccine.

AveXis, the Swiss pharma’s gene therapy subsidiary, has agreed to manufacture the vaccine being developed by Massachusetts Eye and Ear and Massachusetts General Hospital. The biotech will begin manufacturing this month, while the vaccine undergoes further preclinical testing. They’ve agreed to provide the vaccine for free for clinical trials beginning in the second half of 2020, but have not disclosed financials for after.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.